

A novel *CHD7* mutation in an adolescent presenting with pubertal and growth delay

M.C. Antoniou^a, T. Bouthors^a, C. Xu^b, M. Santi^a, F. Phan-Hug^a, E. Elowe-Gruau^a, S. Stoppa-Vaucher^a, A. Van der Sloot^c, D. Cassatella^b, C. Richard^d, A. Dwyer^b, N. Pitteloud^{a,b}, M. Hauschild^a

a. Department of Pediatric Endocrinology and Diabetology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
 b. Service of Endocrinology, Diabetes and Metabolism, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
 c. Institute for Research in Immunology and Cancer (IRIC), University of Montreal
 d. Otorhinolaryngology Service, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Background

Mutations in the gene encoding the Chromodomain Helicase DNA-binding protein 7 (*CHD7*) are found in ~60%¹ of patients with **CHARGE** syndrome (Coloboma, Heart Defects, Choanal Atresia, Retarded growth and development, Genital hypoplasia, Ear abnormalities and/or hearing problems) and in 6% of patients with Kallmann syndrome².

Clinical diagnostic criteria (Verloes 2005)²:

Major criteria (3 C's):

- Coloboma
- Choanal atresia
- Hypoplastic semi-circular canals

Minor criteria

- Rhombencephalic dysfunction
- Hypothalamo-hypophyseal dysfunction
- Abnormal middle or external ear
- Malformation of mediastinal organs
- Mental retardation

Diagnostic CHARGE criteria interpretation:

- **Typical** : 3 major or 2 major & 2 minor criteria
- **Partial/incomplete** : 2 major & 1 minor criteria
- **Atypical** : 2 major or 1 major & 3 minor criteria

Objective

To describe the diagnostic challenges of CHARGE syndrome using the example of a patient harboring a novel *CHD7* mutation

Case Presentation

A 14 year-old male presented for evaluation of delayed growth and puberty.

Family history:

- Delayed puberty in both parents

Past medical history:

- Born full term; eutrophic after an uneventful pregnancy
- Surgical repair of bilateral choanal atresia (5th day of life)
- Normal development, began walking at 18-months, history of imbalance during childhood - not formally investigated

Clinical examination:

- Anthropometry: Height -2.04 SDS; Weight -1.74 SDS
- Tanner: A1P2G1; Micropenis (4x1cm)⁴
- Ogival palate, left helix anteversion, low set ears



Investigations:

- Cardiac US and ECG: normal
- Ophthalmologic exam: normal
- ORL: conductive hypoacusia, abnormal lateral and posterior semicircular canal function
- Olfactory testing ("Sniffin'-Sticks"): anosmia
- MRI (see right)
 - ✓ semi-circular canal hypoplasia
 - ✓ olfactory bulb hypoplasia
 - ✓ decreased anterior pituitary volume (160mm³)
 - ✓ vestibular malformation, cochlear & R 7th cranial nerve malformation


Laboratory testing:

- Partial gonadotropin deficiency, otherwise normal pituitary function


	Patient	Reference value	LHRH Stimulation Test	
			LH	FSH
Testosterone	nmol/l	0.3	0.1-17.6	
Prolactin	µg/l	9.2	<20	
TSH	mU/l	2.19	0.5 - 4.5	0'
freeT4	pmol/l	16	9 - 25	15'
IGF-1	µg/l	254	212 - 1043	30'
IGFBP3	mg/l	5.4	3.2 - 10.4	60'
ACTH	pg/ml	12	10 - 60	90'
Cortisol	nmol/l	315	170 - 630	120'
AMH	pmol/l	438	5-800	
Inhibin-B	pg/ml	86.4	60-300	




Bilateral choanal atresia (CT, 3rd day of life)



Decreased anterior pituitary volume (MRI, 14Y)



Mondini dysplasia of the partition of the cochlea (MRI, 14Y)




Abnormal lateral and posterior semicircular canals (MRI, 14Y)



Olfactory bulb aplasia (R) and hypoplasia (L) (MRI, 14Y)

Genetic testing (Sanger sequencing)

- *De novo* heterozygous *CHD7* mutation (c.4234T>G, p.Tyr1412Asp) located in the Helicase C domain
- A private variant not found in either the 1'000 Genomes or ExAC databases
- Predicted to be deleterious by 10/10 *in silico* prediction algorithms.



The patient fulfilled criteria for typical CHARGE syndrome.

Discussion & conclusions

We describe a novel *CHD7* mutation (c.4234T>G, p. Tyr1412Asp) located in the Helicase C domain in a patient with CHARGE syndrome who remained undiagnosed until adolescence, despite the presence of suggestive features. Genetic testing promotes the broadening of phenotypic and genotypic spectrum of CHARGE syndrome and may give insight to the mild end of phenotypic spectrum, ensuring optimal follow up and appropriate genetic counselling.

References

1. Lalani SR, Safiullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, McPherson JD, Gibbs RA, White LD, Hefner M, Davenport SL, Graham JM, Bacino CA, Glass NL, Towbin JA, Craigen WJ, Neish SR, Lin AE, Belmont JW. Spectrum of *CHD7* mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. *Am J Hum Genet.* 2006 Feb;78(2):303-14.
2. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dodé C, Dunkel L, Dwyer AA, Giacobini P, Hardelin JP, Juul A, Maghnie M, Pitteloud N, Prevot V, Raivio T, Tena-Sempere M, Quinton R, Young J. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. *Nat Rev Endocrinol.* 2015 Sep; 11(9):547-64
3. Verloes A. Updated diagnostic criteria for CHARGE syndrome: a proposal. *Am J Med Genet A.* 2005 Mar 15; 133A(3):306-8
4. Hall J. Handbook of normal physical measurements

